Lipoprotein(a) and lipid profile in patients with atrial fibrillation.

Background: Atrial fibrillation (AF) is well-known risk factor for cardiac embolic events, especially cerebrovascular events. The association between AF and lipid markers was evaluated. Among all these markers, lipoprotein(a), or (Lp(a), was also investigated.

Lipoprotein (a) in patients on hemodialysis.

Lipoprotein (a) [Lp(a)] may produce thrombogenic effects by modulating the fibrinolytic system. Elevated levels of Lp(a) have also been associated with an increased risk for atherosclerosis. Because atherosclerosis is more prevalent among patients with end-stage renal disease, the role of Lp(a) among patients on hemodialysis is analyzed.